LLY

1,008.12

+1.46%↑

JNJ

209.41

+2.16%↑

ABBV

222.68

-1.08%↓

UNH

336.6

+2.73%↑

AZN

90.64

-0.59%↓

LLY

1,008.12

+1.46%↑

JNJ

209.41

+2.16%↑

ABBV

222.68

-1.08%↓

UNH

336.6

+2.73%↑

AZN

90.64

-0.59%↓

LLY

1,008.12

+1.46%↑

JNJ

209.41

+2.16%↑

ABBV

222.68

-1.08%↓

UNH

336.6

+2.73%↑

AZN

90.64

-0.59%↓

LLY

1,008.12

+1.46%↑

JNJ

209.41

+2.16%↑

ABBV

222.68

-1.08%↓

UNH

336.6

+2.73%↑

AZN

90.64

-0.59%↓

LLY

1,008.12

+1.46%↑

JNJ

209.41

+2.16%↑

ABBV

222.68

-1.08%↓

UNH

336.6

+2.73%↑

AZN

90.64

-0.59%↓

Search

Twist Bioscience Corp

Открыт

СекторЗдравоохранение

31.98 -0.87

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

31.67

Макс.

33.19

Ключевые показатели

By Trading Economics

Доход

-48M

-27M

Продажи

3M

99M

Прибыль на акцию

-0.45

Рентабельность продаж

-27.41

Сотрудники

979

EBITDA

3.2M

-21M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+15.92% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

101M

2B

Предыдущая цена открытия

32.85

Предыдущая цена закрытия

31.98

Новостные настроения

By Acuity

50%

50%

195 / 374 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Twist Bioscience Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

10 дек. 2025 г., 22:02 UTC

Отчет

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 дек. 2025 г., 21:46 UTC

Отчет

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 дек. 2025 г., 23:52 UTC

Приобретения, слияния, поглощения

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 дек. 2025 г., 23:43 UTC

Обсуждения рынка

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 дек. 2025 г., 23:36 UTC

Обсуждения рынка

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 дек. 2025 г., 23:20 UTC

Отчет

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 дек. 2025 г., 23:15 UTC

Отчет

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 дек. 2025 г., 22:59 UTC

Обсуждения рынка
Отчет
Приобретения, слияния, поглощения

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 дек. 2025 г., 22:45 UTC

Обсуждения рынка

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 дек. 2025 г., 22:40 UTC

Отчет

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 дек. 2025 г., 22:06 UTC

Приобретения, слияния, поглощения

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 дек. 2025 г., 22:06 UTC

Отчет

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 дек. 2025 г., 22:02 UTC

Отчет

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 дек. 2025 г., 22:00 UTC

Отчет

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 дек. 2025 г., 21:53 UTC

Отчет

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 дек. 2025 г., 21:50 UTC

Приобретения, слияния, поглощения

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 дек. 2025 г., 21:50 UTC

Обсуждения рынка
Отчет
Приобретения, слияния, поглощения

Financial Services Roundup: Market Talk

10 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Health Care Roundup: Market Talk

10 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Auto & Transport Roundup: Market Talk

10 дек. 2025 г., 21:45 UTC

Приобретения, слияния, поглощения

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 дек. 2025 г., 21:33 UTC

Отчет

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 дек. 2025 г., 21:32 UTC

Отчет

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 дек. 2025 г., 21:28 UTC

Приобретения, слияния, поглощения

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 дек. 2025 г., 21:25 UTC

Отчет

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 дек. 2025 г., 21:18 UTC

Приобретения, слияния, поглощения

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 дек. 2025 г., 21:16 UTC

Отчет

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 дек. 2025 г., 21:15 UTC

Приобретения, слияния, поглощения

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 дек. 2025 г., 21:15 UTC

Отчет

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 дек. 2025 г., 21:14 UTC

Отчет

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 дек. 2025 г., 21:14 UTC

Отчет

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Сравнение c конкурентами

Изменение цены

Twist Bioscience Corp Прогноз

Целевая цена

By TipRanks

15.92% рост

Прогноз на 12 месяцев

Средняя 38 USD  15.92%

Максимум 42 USD

Минимум 32 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Twist Bioscience Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

5 ratings

5

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

31.56 / 38.6884Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

195 / 374Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat